Lu Yuanfei, Feng Na, Du Yongzhong, Yu Risheng
Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, China.
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China.
Nanomaterials (Basel). 2022 Aug 17;12(16):2832. doi: 10.3390/nano12162832.
Hepatocellular carcinoma (HCC) is still a main health concern around the world, with a rising incidence and high mortality rate. The tumor-promoting components of the tumor microenvironment (TME) play a vital role in the development and metastasis of HCC. TME-targeted therapies have recently drawn increasing interest in the treatment of HCC. However, the short medication retention time in TME limits the efficiency of TME modulating strategies. The nanoparticles can be elaborately designed as needed to specifically target the tumor-promoting components in TME. In this regard, the use of nanomedicine to modulate TME components by delivering drugs with protection and prolonged circulation time in a spatiotemporal manner has shown promising potential. In this review, we briefly introduce the obstacles of TME and highlight the updated information on nanoparticles that modulate these obstacles. Furthermore, the present challenges and future prospects of TME modulating nanomedicines will be briefly discussed.
肝细胞癌（HCC）仍是全球主要的健康问题，其发病率不断上升且死亡率很高。肿瘤微环境（TME）中的肿瘤促进成分在HCC的发生和转移中起着至关重要的作用。针对TME的疗法最近在HCC治疗中引起了越来越多的关注。然而，药物在TME中的保留时间较短限制了TME调节策略的效率。纳米颗粒可以根据需要进行精心设计，以特异性靶向TME中的肿瘤促进成分。在这方面，利用纳米药物通过时空方式递送具有保护作用和延长循环时间的药物来调节TME成分已显示出有前景的潜力。在本综述中，我们简要介绍了TME的障碍，并强调了关于调节这些障碍的纳米颗粒的最新信息。此外，还将简要讨论TME调节纳米药物目前面临的挑战和未来前景。
